VKTX250117P54000
- 20.68
- 0.000.00%
Viking Therapeutics Newsroom
10 Health Care Stocks With Whale Alerts In Today's Session
Viking M&A Closes $115 Million in Q4 2024 Transactions, Driven by Election Effect and Strong Market Outlook for 2025
Allurion (ALUR.US) stock price surged violently; its new weight loss therapy can maintain muscle mass.
On Thursday, Allurion's stock price soared 80% in after-hours trading, following reports that the company plans to conduct clinical research combining its gastric balloon weight loss product with GLP-1 drugs.
Allurion Stock Soars 70% on Weight-loss Therapy Update
Viking Therapeutics (VKTX) Stock Could Rise 200%, Says Jefferies
Jefferies Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $110
Viking Therapeutics: Strategic Growth and Strong Buy Rating Amidst Advancements in Obesity Drug Pipeline
This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly. -- Barrons.com
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
Top 3 Health Care Stocks That Could Blast Off This Quarter
Viking Therapeutics, Inc. (VKTX) Increases Yet Falls Behind Market: What Investors Need to Know
What's Next for Viking Therapeutics? Here's How the Company Can Scale Up.
Express News | Viking Therapeutics Shares Spike Higher; Last up 3.4%
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $164
Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
Why Viking Therapeutics (VKTX) Is the Biotech With Biggest Upside Potential
Viking Therapeutics' VK2735: A Promising Contender in the Weight-Loss Market With Superior Efficacy Profile